Art. -Nr.: HY-19735

KJ Pyr 9

Name: KJ Pyr 9
Brand: MedChemExpress
SKU: HY-19735
Price: 66.00 USD
Availability: InStock
Rating: 5 (7 reviews)

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

KJ Pyr 9 is an inhibitor of MYC with a K_d of 6.5 nM in in vitro assay.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.24%
CAS. Nr.: 581073-80-5
Formel: C₂₂H₁₅N₃O₄
Molecular Weight:385.37

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

KJ Pyr 9 Chemical Structure

CAS. Nr.: 581073-80-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

KJ Pyr 9 is an inhibitor of MYC with a K_d of 6.5 nM in in vitro assay.

IC₅₀ & Target

Kd: 6.5±1.0 nM (MYC)^[1]

In Vitro

KJ Pyr 9 (KJ-Pyr-9) interferes with MYC-MAX complex formation in the cell in a protein fragment complementation assay^[1].
KJ Pyr 9 specifically inhibits MYC-induced oncogenic transformation in cell culture and has no or only weak effects on the oncogenic activity of several unrelated oncoproteins^[1].
KJ Pyr 9 preferentially interferes with the proliferation of MYC-overexpressing human and avian cells and specifically reduces the MYC-driven transcriptional signature^[1].
KJ Pyr 9 against three cell lines (NCI-H460, MDA-MB-231, and SUM-159PT) is tested known to be dependent on increased MYC activity^[1].
KJ Pyr 9 can inhibit the proliferation of all cell lines with IC₅₀ values between 5 and 10 μM^[1].
KJ Pyr 9 is more sensitive (IC₅₀ values between 1 and 2.5 μM) for the proliferation of Burkitt lymphoma cell lines with constitutively high expression of c-MYC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .

In Vivo

KJ Pyr 9 (i.p.; 10 mg/kg; daily; for 31 d) has the ability to halt tumor growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 581073-80-5
Appearance Solid
Molecular Weight 385.37
Formel C₂₂H₁₅N₃O₄
Color Light yellow to yellow
SMILES

O=C(N)C1=CC=C(C2=CC(C3=CC=CO3)=NC(C4=CC=C([N+]([O-])=O)C=C4)=C2)C=C1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (7)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nature

Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. [Abstract]

2024 Jun;630(8018):968-975. PMID: 38867043

KJ Pyr 9 purchased from MedChemExpress. Usage Cited in: Nature. 2024 Jun;630(8018):968-975. [Abstract]

Percent viability, MFI of PD-1 and percent PD-1+ of primary BMDMs stimulated with LPS (1 μg/mL) and treated with c-Myc inhibitors (KJ Pyr 9 10 μg/mL and 10058-F4 10 μg/mL), mTOR inhibitor (Rapamycin 250 ng/mL), AMPK agonist (AICAR 2 μg/mL) and NF-κB inhibitor (BMS-345541 1.2 μg/mL) for 24 h.

KJ Pyr 9 purchased from MedChemExpress. Usage Cited in: Nature. 2024 Jun;630(8018):968-975. [Abstract]

Percent viability, MFI of PD-1 and percent PD-1+ of immortalized cas9 BMDMs treated with c-Myc inhibitors (KJ Pyr 9 10 μg/mL and 10058-F4 10 μg/mL), mTOR inhibitor (Rapamycin 350 ng/mL), AMPK agonist (AICAR 5 μg/mL) and NF-κB inhibitor (BMS-345541 300 μg/mL) for 24 h.
Nat Genet

MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch. [Abstract]

2024 Apr;56(4):663-674. PMID: 38454021
Cell Mol Immunol

Myc inhibition tips the immune balance to promote antitumor immunity. [Abstract]

2022 Sep;19(9):1030-1041. PMID: 35962189

KJ Pyr 9 purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Sep;19(9):1030-1041. [Abstract]

We first compared the antitumor effects of Mycro3, ML327, and KJ Pyr 9, three Myc inhibitors commercially available to us, in the B16F10 mouse melanoma model.
Cancer Res

SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast Cancer. [Abstract]

2025 Sep 10. PMID: 40928937
Cell Rep Med

N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer. [Abstract]

2023 Apr 18;4(4):101002. PMID: 37044095

KJ Pyr 9 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2023 Apr 18;4(4):101002. [Abstract]

Quantification of cell proliferation by EdU incorporation over 2 h after 48-h pre-treatment with vehicle, 3 μM alpelisib, and/or 5 mM NAC, and/or 20 μM KJ-Pyr-9.

KJ Pyr 9 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2023 Apr 18;4(4):101002. [Abstract]

Quantification of glycolysis, measured as ECAR (in mpH/min) by an extracellular flux analyzer. T47D CTRL and NF1 KO cells were treated for 24 h with vehicle, 20 μM KJ-Pyr-9, or 5 mM NAC prior to the assay.
J Exp Med

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer. [Abstract]

2023 Nov 6;220(11):e20211743. PMID: 37642941
bioRxiv

2023.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (324.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5949 mL

12.9745 mL

25.9491 mL

5 mM

0.5190 mL

2.5949 mL

5.1898 mL

10 mM

0.2595 mL

1.2975 mL

2.5949 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.49 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (5.40 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hart JR, et al. Inhibitor of MYC identified in a Kröhnke pyridine library. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12556-61. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5949 mL	12.9745 mL	25.9491 mL	64.8727 mL
	5 mM	0.5190 mL	2.5949 mL	5.1898 mL	12.9745 mL
	10 mM	0.2595 mL	1.2975 mL	2.5949 mL	6.4873 mL
	15 mM	0.1730 mL	0.8650 mL	1.7299 mL	4.3248 mL
	20 mM	0.1297 mL	0.6487 mL	1.2975 mL	3.2436 mL
	25 mM	0.1038 mL	0.5190 mL	1.0380 mL	2.5949 mL
	30 mM	0.0865 mL	0.4325 mL	0.8650 mL	2.1624 mL
	40 mM	0.0649 mL	0.3244 mL	0.6487 mL	1.6218 mL
	50 mM	0.0519 mL	0.2595 mL	0.5190 mL	1.2975 mL
	60 mM	0.0432 mL	0.2162 mL	0.4325 mL	1.0812 mL
	80 mM	0.0324 mL	0.1622 mL	0.3244 mL	0.8109 mL
	100 mM	0.0259 mL	0.1297 mL	0.2595 mL	0.6487 mL

Bioz

Keywords

KJ Pyr 9

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

KJ Pyr 9

Publications Citing Use of MedChemExpress (MCE) KJ Pyr 9